BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15522061)

  • 1. Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center.
    Damaj G; Mohty M; Vey N; Dincan E; Bouabdallah R; Faucher C; Stoppa AM; Gastaut JA
    Eur J Haematol; 2004 Dec; 73(6):402-6. PubMed ID: 15522061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical features of multiple myeloma patients with extramedullary disease: a report of 40 cases from a single center].
    Chen HF; Fu WJ; Wang DX; Yuan ZG; Chen YB; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):655-8. PubMed ID: 18399168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of extramedullary plasmacytoma.
    Galieni P; Cavo M; Pulsoni A; Avvisati G; Bigazzi C; Neri S; Caliceti U; Benni M; Ronconi S; Lauria F
    Haematologica; 2000 Jan; 85(1):47-51. PubMed ID: 10629591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
    Terpos E; Rezvani K; Basu S; Milne AE; Rose PE; Scott GL; Rahemtulla A; Samson D; Apperley JF
    Eur J Haematol; 2005 Nov; 75(5):376-83. PubMed ID: 16191086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
    Radocha J; Maisnar V
    Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
    Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
    Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.
    Minnema MC; van de Donk NW; Zweegman S; Hegenbart U; Schonland S; Raymakers R; Zijlmans JM; Kersten MJ; Bos GM; Lokhorst HM
    Bone Marrow Transplant; 2008 May; 41(9):779-84. PubMed ID: 18195681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
    Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
    Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic.
    Nascimento AF; Raut CP; Fletcher CD
    Am J Surg Pathol; 2008 Dec; 32(12):1896-904. PubMed ID: 18813119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
    Jaksic W; Trudel S; Chang H; Trieu Y; Qi X; Mikhael J; Reece D; Chen C; Stewart AK
    J Clin Oncol; 2005 Oct; 23(28):7069-73. PubMed ID: 16129840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
    Talamo G; Angtuaco E; Walker RC; Dong L; Miceli MH; Zangari M; Tricot G; Barlogie B; Anaissie E
    J Clin Oncol; 2005 Aug; 23(22):5217-23. PubMed ID: 15955903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid-disseminated meningioma.
    Chamberlain MC; Glantz MJ
    Cancer; 2005 Apr; 103(7):1427-30. PubMed ID: 15690330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.